The changing relationship between HbA1c and FPG according to different FPG ranges
- 193 Downloads
Since the American Diabetes Association included hemoglobin A1c (HbA1c) in the diagnostic criteria for diabetes in 2010, the clinical use of HbA1c has remained controversial. We explored the use of HbA1c for diagnosing diabetes and intermediate hyperglycemia in comparison with fasting plasma glucose (FPG).
We screened 3710 adult subjects (mean age = 55.24 years) comprising 1704 males and 2006 females. We drew an receiver operating characteristic (ROC) curve to evaluate the ability of HbA1c to diagnose diabetes and intermediate hyperglycemia according to FPG. We used Kappa coefficient and Pearson’s correlation coefficient to evaluate the relationship between HbA1c and FPG in different FPG ranges.
The areas under ROC curve to diagnose diabetes and intermediate hyperglycemia were 0.859 (95 % CI 0.827–0.892) and 0.633 (95 % CI 0.615–0.651). The kappa coefficients between FPG and HbA1c for diagnosis of diabetes and intermediate hyperglycemia were 0.601 (P < 0.001) and 0.104 (P < 0.001). The Pearson’s correlation coefficient of FPG and HbA1c was 0.640 (P < 0.001), but when we classified FPG as normal, intermediate hyperglycemia and diabetes, the coefficients became 0.07 (P = 0.002), 0.185 (P < 0.001) and 0.760 (P < 0.001), respectively.
The relationship between HbA1c and FPG changed according to the different FPG ranges. When FPG was higher, the relationship was stronger. HbA1c and FPG were highly consistent in diagnosing diabetes, but they were not in predicting intermediate hyperglycemia.
KeywordsHemoglobin A1c (HbA1c) Fasting plasma glucose (FPG) Diabetes
Compliance with ethical standards
Conflict of interest
The study was approved by the Ethics Committee of China Medical University.
Informed and written consent was obtained from each participant.
- 4.Bianchi C, Miccoli R, Bonadonna RC, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo GM, Leonetti F, Del Prato S, Investigators GENFIEV (2012) Pathogenetic mechanisms and cardiovascular risk: differences between HbA1c and oral glucose tolerance test for the diagnosis of glucose tolerance. Diabetes Care 35(12):2607–2612CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Lipska KJ, De Rekeneire N, Van Ness PH, Johnson KC, Kanaya A, Koster A, Strotmeyer ES, Goodpaster BH, Harris T, Gill TM, Inzucchi SE (2010) Identifying dysglycemic states in older adults: implications of the emerging use of hemoglobin A1c. J Clin Endocrinol Metab 95:5289–5295CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Kumaravel B, Bachmann MO, Murray N, Dhatariya K, Fenech M, John WG, Scarpello TJ, Sampson MJ, University of East Anglia Impaired Fasting Glucose (UEA-IFG) Study Group (2012) Use of haemoglobin A1c to detect impaired fasting glucose or type 2 diabetes in a United Kingdom community based population. Diabetes Res Clin Pract 96(2):211–216CrossRefPubMedGoogle Scholar
- 9.Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA, Eschwege E, DESIR Study Group (2006) The DESIR Study Group: use of HbA1C in predicting progression to diabetes in French men and women data from an epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care 29(7):1619–1625CrossRefPubMedGoogle Scholar
- 18.Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G, 2010 China Noncommunicable Disease Surveillance Group (2013) Prevalence and control of diabetes in Chinese adults. JAMA 310(9):948–959CrossRefPubMedGoogle Scholar